Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Intangibles (2017 - 2021)

Historic Intangibles for Avalo Therapeutics (AVTX) over the last 5 years, with Q4 2021 value amounting to $38000.0.

  • Avalo Therapeutics' Intangibles fell 9760.25% to $38000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $38000.0, marking a year-over-year decrease of 9760.25%. This contributed to the annual value of $38000.0 for FY2021, which is 9760.25% down from last year.
  • As of Q4 2021, Avalo Therapeutics' Intangibles stood at $38000.0, which was down 9760.25% from $304000.0 recorded in Q3 2021.
  • Over the past 5 years, Avalo Therapeutics' Intangibles peaked at $33.1 million during Q1 2018, and registered a low of $38000.0 during Q4 2021.
  • Its 5-year average for Intangibles is $12.7 million, with a median of $2.7 million in 2020.
  • As far as peak fluctuations go, Avalo Therapeutics' Intangibles crashed by 888.05% in 2019, and later crashed by 9760.25% in 2021.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Intangibles stood at $17.7 million in 2017, then plummeted by 78.68% to $3.8 million in 2018, then crashed by 35.56% to $2.4 million in 2019, then crashed by 34.67% to $1.6 million in 2020, then plummeted by 97.6% to $38000.0 in 2021.
  • Its Intangibles stands at $38000.0 for Q4 2021, versus $304000.0 for Q3 2021 and $732000.0 for Q2 2021.